Aurinia Pharmaceuticals (NASDAQ:AUPH) Releases Earnings Results, Meets Expectations

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) issued its earnings results on Thursday. The biotechnology company reported $0.01 EPS for the quarter, meeting analysts’ consensus estimates of $0.01, Briefing.com reports. The business had revenue of $57.10 million during the quarter, compared to analysts’ expectations of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.75%. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.08) earnings per share.

Aurinia Pharmaceuticals Trading Down 2.0 %

Aurinia Pharmaceuticals stock traded down $0.11 during midday trading on Friday, hitting $5.50. 2,032,563 shares of the stock were exchanged, compared to its average volume of 1,420,359. Aurinia Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $11.15. The stock has a market capitalization of $786.61 million, a price-to-earnings ratio of -12.79 and a beta of 1.44. The stock’s 50-day simple moving average is $5.52 and its 200 day simple moving average is $5.77. The company has a current ratio of 5.60, a quick ratio of 5.05 and a debt-to-equity ratio of 0.19.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.